Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?

Novo NVO announced two important regulatory updates in Europe late last week, putting its Rare Disease portfolio back in focus. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of denecimig, under the brand name Frehemgo, for hemophilia A in adults and children, with or without inhibitors. The CHMP also issued a positive opinion recommending once-weekly Sogroya (somapacitan) for children with idiopathic short stature (ISS) or unexplained shortness. While both decisions still require final European Commission (EC) action, they could strengthen Novo's growth prospects beyond its core cardiometabolic franchise. Frehemgo could add a differentiated product to Novo's hemophilia portfolio.